Download PDF
Thromb Haemost 2000; 84(06): 1132-1133
DOI: 10.1055/s-0037-1614192
Letters to the Editor
Schattauer GmbH

Dependence on Prothrombin for Inhibition of Activated Protein C Activity by Lupus Antibodies

Susan L. Field
1   From the Centre for Thrombosis and Vascular Research, School of Pathology, University of New South Wales and Department of Haematology, South Eastern Laboratory Services, Sydney NSW, Australia
,
Colin N. Chesterman
1   From the Centre for Thrombosis and Vascular Research, School of Pathology, University of New South Wales and Department of Haematology, South Eastern Laboratory Services, Sydney NSW, Australia
,
Philip J. Hogg
1   From the Centre for Thrombosis and Vascular Research, School of Pathology, University of New South Wales and Department of Haematology, South Eastern Laboratory Services, Sydney NSW, Australia
› Author AffiliationsThis study was supported by grants from the National Health and Medical Research Council of Australia, the National Heart Foundation of Australia, and an Infrastructure Grant from the NSW Health Department.
Further Information

Publication History

Received 04 July 2000

Accepted after revision 11 August 2000

Publication Date:
13 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Brighton TA, Chesterman CN. Antiphospholipid antibodies and thrombosis. Bailliére’s Clinical Haematology 1994; 07: 541-57.
    PubMedGoogle Scholar
  • 2 Field SL, Hogg PJ, Daly EB, Dai Y-P, Murray B, Owens D, Chesterman CN. Lupus anticoagulants form immune complexes with prothrombin and phospholipid that can augment thrombin production in flow. Blood 1999; 94: 3421-31.
    CrossrefPubMedGoogle Scholar
  • 3 van de Waart P, Hemker HC, Lindhout T. Interaction of prothrombin with factor Va-phospholipid complexes. Biochemistry 1984; 23: 2838-42.
    CrossrefPubMedGoogle Scholar
  • 4 Nicolaes GAF, Tans G, Thomassen MCLGD, Hemker HC, Pabinger I, Varadi K, Schwarz HP, Rosing J. Peptide bond cleavage and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 21158-66.
    CrossrefPubMedGoogle Scholar
  • 5 Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, Tracy PB. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals. J Biol Chem 1995; 270: 20794-800.
    CrossrefPubMedGoogle Scholar
  • 6 Malia RG, Kitchen S, Greaves M, Preston FE. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haem 1990; 76: 101-7.
    CrossrefPubMedGoogle Scholar
  • 7 Borrell M, Sala N, de Castellarnau C, Lopez S, Gari M, Fontcuberta J. Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 1992; 68: 268-72.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism?. Blood 1993; 81: 2618-25.
    PubMedGoogle Scholar
  • 9 Marciniak E, Romond E. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant. Blood 1989; 74: 2426-32.
    PubMedGoogle Scholar
  • 10 Amer L, Kisiel W, Serales RP, Williams Jr RC. Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies and thrombosis. Thromb Res 1990; 57: 247-58.
    CrossrefPubMedGoogle Scholar
  • 11 Lo SCL, Salem HH, Howard MA, Oldmeadow MJ, Firkin BG. Studies of natural anticoagulant proteins and anticardiolipin antibodies in patients with the lupus anticoagulant. Brit J Haematol 1990; 76: 380-6.
    CrossrefPubMedGoogle Scholar